Levetiracetam in lactation: How much is excreted into human breast milk?

breastfeeding women breastmilk excretion infant exposure levetiracetam levetiracetam safety in breastfeeding

Journal

British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323

Informations de publication

Date de publication:
01 2022
Historique:
revised: 20 05 2021
received: 11 11 2020
accepted: 22 05 2021
pubmed: 17 6 2021
medline: 12 4 2022
entrez: 16 6 2021
Statut: ppublish

Résumé

In breastfeeding women, anti-epileptic therapy can lead to infant toxicities, even with newer anti-epileptic drugs such as levetiracetam. This study assessed levetiracetam breastmilk excretion and its correlation with the maternal oral dose and serum concentrations. Women with epilepsy treated with levetiracetam were recruited to this study and completed a questionnaire. Levetiracetam concentrations were determined in serial breastmilk samples (pre-dose to 12 h post-dose period) and in a single pre-dose maternal serum sample. Twenty breastfeeding women and 21 infants (one woman with twins; 16 fully and five partially breastfed infants) participated in this study. The trough breastmilk/serum ratio of levetiracetam was 0.98 ± 0.20. The infant levetiracetam daily dose was 5.39 ± 1.96 and 2.70 ± 0.98 mg Infant levetiracetam exposure via the breastmilk was close to the safety thresholds (trough breastmilk/serum ratio slightly below 1, RID > 10% in fully breastfed infants), and infant somnolescence reports could be related to exposure of the infants to levetiracetam via breastmilk. Further studies are warranted to reveal the short- and long-term safety of levetiracetam in breastfeeding.

Identifiants

pubmed: 34131926
doi: 10.1111/bcp.14940
doi:

Substances chimiques

Anticonvulsants 0
Levetiracetam 44YRR34555

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

199-205

Informations de copyright

© 2021 British Pharmacological Society.

Références

Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the "common" neurologic disorders? Neurology. 2007;68(5):326-337.
Harden CL, Hopp J, Ting TY, et al. Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): obstetrical complications and change in seizure frequency: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology. 2009;73:126-132.
Section on Breastfeeding. Breastfeeding and the use of human milk. Pediatrics. 2012;129(3):e827-e841.
Reiter SF, Veiby G, Daltveit AK, Engelsen BA, Gilhus NE. Psychiatric comorbidity and social aspects in pregnant women with epilepsy - the Norwegian Mother and Child Cohort Study. Epilepsy Behav. 2013;29(2):379-385.
Bjork MH, Veiby G, Reiter SC, et al. Depression and anxiety in women with epilepsy during pregnancy and after delivery: a prospective population-based cohort study on frequency, risk factors, medication, and prognosis. Epilepsia. 2015;56(1):28-39.
Bernard-Bonnin A-C. Maternal depression and child development. Paediatr Child Health. 2004;9(8):575-583.
Murray L, Fiori-Cowley A, Hooper R, Cooper P. The impact of postnatal depression and associated adversity on early mother-infant interactions and later infant outcome. Child Dev. 1996;67(5):2512-2526.
Engstrom JL. Promoting and supporting breastfeeding: health care providers make a difference. J Midwifery Womens Health. 2007;52(6):543-544.
Tomson T, Palm R, Kallen K, et al. Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. Epilepsia. 2007;48(6):1111-1116.
Westin AA, Reimers A, Helde G, Nakken KO, Brodtkorb E. Serum concentration/dose ratio of levetiracetam before, during and after pregnancy. Seizure. 2008;17(2):192-198.
Lopez-Fraile IP, Cid AO, Juste AO, Modrego PJ. Levetiracetam plasma level monitoring during pregnancy, delivery, and postpartum: clinical and outcome implications. Epilepsy Behav. 2009;15(3):372-375.
Pennell PB. Is breast milk the best for babies of mothers on levetiracetam? Epilepsy Curr. 2006;6(1):22-24.
Schulz M, Schmoldt A. Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Pharmazie. 2003;58(7):447-474.
Bennett PN, Matheson I. Drugs and human lactation: a guide to the content and consequences of drugs, micronutrients, radiopharmaceuticals and environmental and occupational chemicals in human milk. Amsterdam: Elsevier; 1988.
Johannessen SI, Helde G, Brodtkorb E. Levetiracetam concentrations in serum and in breast milk at birth and during lactation. Epilepsia. 2005;46(5):775-777.
Kramer G. Levetiracetam accumulation in human breast milk. Epilepsia. 2002;43:105-105.
Keppra (levetiracetam) tablets and oral solution [prescribing information]. Smyrna, GA: UCB Inc; October 2019.
Verstegen RHJ, Anderson PO, Ito S. Infant drug exposure via breast milk. Br J Clin Pharmacol. 2020:1-17.
Birnbaum AK, Meador KJ, Karanam A, et al. Antiepileptic drug exposure in infants of breastfeeding mothers with epilepsy. JAMA Neurol. 2020;77(4):441-450.

Auteurs

Natalie Dinavitser (N)

Clinical Pharmacology and Toxicology Unit, Shamir (Assaf Harofeh) Medical Center, affiliated to the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Elkana Kohn (E)

Clinical Pharmacology and Toxicology Unit, Shamir (Assaf Harofeh) Medical Center, affiliated to the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

Maya Berlin (M)

Clinical Pharmacology and Toxicology Unit, Shamir (Assaf Harofeh) Medical Center, affiliated to the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

Nurit Brandriss (N)

Biochemistry Laboratory, Shamir (Assaf Harofeh) Medical Center, affiliated to the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

Adina Bar-Chaim (A)

Biochemistry Laboratory, Shamir (Assaf Harofeh) Medical Center, affiliated to the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

Rimona Keidar (R)

Neonatal Intensive Care Unit, Shamir (Assaf Harofeh) Medical Center, affiliated to the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

Ayelet Livne (A)

Neonatal Intensive Care Unit, Shamir (Assaf Harofeh) Medical Center, affiliated to the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

David Stepensky (D)

Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Matitiahu Berkovitch (M)

Clinical Pharmacology and Toxicology Unit, Shamir (Assaf Harofeh) Medical Center, affiliated to the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

Revital Sheinberg (R)

Clinical Pharmacology and Toxicology Unit, Shamir (Assaf Harofeh) Medical Center, affiliated to the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH